University of South Florida, One Tampa General Circle, Tampa General Hospital, Tampa, FL 33601, USA.
Pancreas. 2011 Oct;40(7):1063-9. doi: 10.1097/MPA.0b013e31821ad8eb.
This study assessed whether pretreatment quality-of-life (QoL) scores could predict the presence of pancreatic malignancy and survival.
Patients with pancreatic lesions completed the SF-36, containing 8 domains: physical functioning, role-physical, role-emotional, bodily pain, vitality, mental health, social functioning, and general health. Data obtained included age, sex, resectability, additional antineoplastic therapy, stage, pathology, and survival. Patients were categorized by pathology (benign vs malignant), stage (local, regional, or distant), resectability (resected vs not), survival (<1 vs >1 year), and their pretreatment QoL scores.
Of the 323 patients assessed, 210 had malignancies. In 6 of the 8 domains, patients with malignancies had lower median QoL scores compared with patients with benign lesions. Of the patients with malignancies, patients surviving at 1 year or less had lower pretreatment scores in all domains. Stage, resection, adjuvant therapy, and vitality score were independent predictors of survival.
Patients with pancreatic malignancies had lower QoL scores than patients with benign pancreatic disease. Patients with malignancies surviving at 1 year or less had lower scores, even after controlling for stage. This suggests that pretreatment QoL scores are associated with pancreatic malignancy and survival.
本研究旨在评估治疗前生活质量（QoL）评分是否可预测胰腺恶性肿瘤的存在和生存情况。
患有胰腺病变的患者完成了 SF-36 量表，其中包含 8 个领域：身体机能、生理职能、生理职能障碍、躯体疼痛、活力、心理健康、社会功能和总体健康。获得的数据包括年龄、性别、可切除性、额外的抗肿瘤治疗、分期、病理和生存情况。患者根据病理（良性与恶性）、分期（局部、区域或远处）、可切除性（已切除与未切除）、生存时间（<1 年与>1 年）和治疗前 QoL 评分进行分类。
在评估的 323 名患者中，210 名患有恶性肿瘤。在 8 个领域中的 6 个领域中，患有恶性肿瘤的患者的 QoL 评分中位数均低于患有良性病变的患者。在患有恶性肿瘤的患者中，生存时间<1 年的患者在所有领域的治疗前评分均较低。分期、切除、辅助治疗和活力评分是生存的独立预测因素。
患有胰腺恶性肿瘤的患者的 QoL 评分低于患有良性胰腺疾病的患者。生存时间<1 年的恶性肿瘤患者的评分较低，即使在控制分期后也是如此。这表明治疗前 QoL 评分与胰腺恶性肿瘤和生存情况有关。
